Chevron, Texaco team up with Baylor to Raise Funds for Alzheimer’s Research

Chevron and Texaco stations are working with Baylor College of Medicine to help “fuel the end of Alzheimer’s disease” through a fundraising campaign launching at select Chevron and Texaco stations in Texas, including Houston, San Antonio, Austin and Dallas.

During September, register and fuel pump signage will encourage Chevron and Texaco customers to make a donation supporting Baylor’s Center for Alzheimer’s and Neurodegenerative Diseases (CAND). CAND’s multidisciplinary team of experts are gaining new insights into Alzheimer’s and related diseases, such as Parkinson’s and amyotrophic lateral sclerosis (ALS), and are working to identify the unique interactions between genes, lifestyle and other factors that trigger neurodegenerative diseases in each person. In doing so, Baylor researchers are paving the way toward highly personalized therapeutics they hope will one day make Alzheimer’s disease a distant memory.

“No two patients with Alzheimer’s disease are alike,” said Dr. Joshua Shulman, director of Baylor’s CAND, associate professor of neurology and an investigator with the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. “What we need for a disorder like that is a more personalized and targeted approach called precision medicine, which tailors treatments to a person’s individual disease type. We’re excited that these Chevron and Texaco stations recognize the importance of this work and are collaborating with us in Texas.”

“Chevron and Texaco retailers and marketers have a long history of support for education, healthcare and economic development in the communities where they live and operate. Solving complex issues like Alzheimer’s and related diseases takes human energy, innovation and collaboration, which is why we are proud to support Baylor’s exceptional multidisciplinary team and research into medical breakthroughs. We are proud that our retailers and marketers in this area are providing customers a way to help contribute to continue Baylor’s research and development of therapeutics,” said Nuray Elci, senior sales manager for Chevron
Americas Fuels.    

An estimated 50 million people worldwide live with Alzheimer’s, which has no cure. By 2050, this number is expected to swell to more than 150 million if no effective treatments or preventive approaches are created. With a 120-year history of collaborative scientific research and important medical breakthroughs, Baylor is taking major steps to tackle Alzheimer’s and other neurodegenerative diseases through research that will translate into critically needed therapeutics.

Learn more about the campaign here www.bcm.edu/fuel.